Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Usmarapride

From Wikipedia, the free encyclopedia

Pharmaceutical compound
Usmarapride
Clinical data
Other namesSUVN-D4010; SUVN-D-4010
Routes of
administration		Oral[1]
Drug classSerotonin5-HT4 receptoragonist
ATC code
  • None
Identifiers
  • 2-[1-(3-methoxypropyl)piperidin-4-yl]-5-(1-propan-2-ylindazol-3-yl)-1,3,4-oxadiazole
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H29N5O2
Molar mass383.496 g·mol−1
3D model (JSmol)
  • CC(C)N1C2=CC=CC=C2C(=N1)C3=NN=C(O3)C4CCN(CC4)CCCOC
  • InChI=1S/C21H29N5O2/c1-15(2)26-18-8-5-4-7-17(18)19(24-26)21-23-22-20(28-21)16-9-12-25(13-10-16)11-6-14-27-3/h4-5,7-8,15-16H,6,9-14H2,1-3H3
  • Key:DWTFBJGTRBMHPG-UHFFFAOYSA-N

Usmarapride (INNTooltip International Nonproprietary Name; developmental code nameSUVN-D4010) is aserotonin5-HT4 receptoragonist which is or was under development for the treatment ofcognitive deficits inAlzheimer's disease andschizophrenia.[1][2][3] It is takenorally.[1]

Pharmacology

[edit]

The drug is apotent andselectivepartial agonist of the serotonin 5-HT4 receptor.[2][3] It is highly selective against the serotonin5-HT3 receptor and other closely related receptors.[2] The drug showscognition- andmemory-enhancing effects,neuroprotective effects, andantidepressant-like effects inpreclinical research.[2][3][4] Itspharmacokinetics andpharmacodynamics have been evaluated in humans.[2][5] In terms ofchemical structure, the drug is anindazolederivative.[6]

Development

[edit]

Usmarapride is under development by Suven Life Sciences.[1] As of September 2023, no recent development has been reported for treatment of Alzheimer's disease and schizophrenia.[1] The drug has reachedphase 1clinical trials for both of these indications.[1]

References

[edit]
  1. ^abcdef"Usmarapride - Suven Life Sciences".AdisInsight. 28 September 2023. Retrieved1 October 2025.
  2. ^abcdeNirogi R, Mohammed AR, Shinde AK, Gagginapally SR, Kancharla DM, Ravella SR, et al. (August 2021). "Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease".J Med Chem.64 (15):10641–10665.doi:10.1021/acs.jmedchem.1c00703.PMID 34251799.
  3. ^abcNirogi R, Grandhi VR, Medapati R, Ganuga N, Abraham R, Thentu JB, et al. (May 2023). "Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling".Eur J Pharmacol.947 175625.doi:10.1016/j.ejphar.2023.175625.PMID 36997046.
  4. ^Abraham R, Subramanian R, Rasheed MA, Ravella SR, Malleshwari D, Thentu JB, et al. (2022)."Usmarapride Oxalate (SUVN-D4010): A Serotonin-4 Receptor Partial Agonist for the Treatment of Cognitive Disorders".Alzheimer's & Dementia.18 (S10) e062167.doi:10.1002/alz.062167.ISSN 1552-5260. Retrieved1 October 2025.
  5. ^Nirogi R, Bhyrapuneni G, Muddana NR, Goyal VK, Pandey SK, Mohammed AR, et al. (May 2021). "First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects".Clin Drug Investig.41 (5):469–482.doi:10.1007/s40261-021-01027-4.PMID 33788154.
  6. ^Dallemagne P, Rochais C (July 2021). "5-HT4R modulators: a patent landscape".Pharm Pat Anal.10 (4):179–181.doi:10.4155/ppa-2021-0017.PMID 34365797.


5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT3–7
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7


Stub icon

Thisdrug article relating to thenervous system is astub. You can help Wikipedia byadding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Usmarapride&oldid=1328699412"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2026 Movatter.jp